Quick status check on Novo, Lilly, and rivals after ADA 2025 – just ahead of Q2 earnings. Introduction Novo Nordisk and Eli Lilly will release their Q2 results on 6 and 7 August.ADA 2025, which wrapped at the end of June, delivered a blitz of new obesity data. Below is a look at every major …
Continue reading “The Obesity Drug Chessboard after ADA2025 with Q2 Earnings in Play ♟️”
Riding the First Wave: Wegovy® and Zepbound® 🏄 GLP-1 weight loss drugs Wegovy® (semaglutide) and Zepbound® (tirzepatide) from Novo Nordisk and Eli Lilly hit markets like a tsunami, when they were approved in June 2021 and November 2023, due to their unprecedented weight-loss efficacy 🌊 The next waves might not be as colossal, but they …
Continue reading “The Next Wave of Obesity Drugs: Opportunities and Risks for Investors 🌊”